Do not inject through clothing , and avoid rubbing the injection site vigorously afterward, which can increase irritation
In the TRIUMPH-4 trial, discontinuation rates due to adverse events ranged from 12.2% to 18.2% with retatrutide
The "research use only" designation is a regulatory category, not a marketing phrase, and material sold under that designation is not intended for, and is not lawful for, human or animal administration [6][14]
The relative differences in weight loss will not be a deterrent, especially if the cost is less, Dr
If you have severe or intolerable side effects such as nausea, vomiting, diarrhea, constipation, worsening of fatigue, and dizziness, your healthcare provider will pause the medication for a few weeks and keep you on the previous tolerable dose
When you compare the skin sensitivity rates across the GLP-1 drug class , an interesting pattern emerges